Whole Exome Sequencing Market worth $884.1 Million by 2018, According to a New Study on ASDReports

Wednesday 8 October 2014, Amsterdam

The new report, now available on ASDReports “Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018” analyzes and studies the major market drivers, threats, opportunities, and challenges.

This report studies the global Whole Exome Sequencing (WES) market over the forecast period of 2013–2018. This market was valued at $326.6 million in 2013 and is poised to grow at a CAGR of 22%, to reach $884.1 million by 2018.

The global whole exome sequencing market is segmented on the basis of technology, products and services, applications, end users, and geography. Based on technology, the whole exome sequencing market is divided between sequencing by synthesis and sequencing by ion semiconductor. Based on products and services, the whole exome sequencing market comprises instruments/platforms/sequencers, kits, sequencing services and data analysis services. Whole exome sequencing kits are further classified into DNA fragmentation, end repair, A-Tailing and size selection, library preparation kits and target enrichment kit.

Based on applications, the whole exome sequencing market is segmented into diagnostics, drug discovery and development, personalized medicine, and agriculture and animal research, among others. The market, by end users, is classified into research centers, academic and government institutions, hospitals and clinics, and pharmaceutical and biotechnology companies.

Based on geography, the market is divided into North America, Europe, Asia, and Rest of the World (RoW). North America is the largest market for whole exome sequencing, followed by Europe and Asia. The Asian market is slated to grow at the highest rate over the next five years.

Over the years, the demand for whole exome sequencing instruments, kits and services is likely to increase. Factors such as the rapidly decreasing costs of sequencing, adoption of WES technology by new consumers, strategic alliances amongst key players and research institutes, and increase in utilization of WES technology for new scientific applications are driving this demand for whole exome sequencing. The most important factor increasing the preference of WES over whole genome sequencing is its low-cost sequencing capability. However, a lack of skilled professionals and high reliability on government grants are some of the factors hindering the growth of the WES market.

Major players in the global whole exome sequencing market include Illumina, Inc. (U.S.) Life Technologies (acquired by Thermo Fisher Scientific, Inc.) (U.S.), Roche NimbleGen, Inc. (U.S.), Agilent Technologies (U.S.), BGI (Beijing Genomics Institute, China), Eurofins Genomics, Inc. (Germany), Sengenics (U.S.), GENEWIZ, Inc. (U.S.), Knome, Inc. (U.S.), Macrogen, Inc. (South Korea), and Ambry Genetics (U.S.), among others.